{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:55:38Z","timestamp":1790934938831,"version":"4.1.0"},"reference-count":64,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Cervical excision increases the risk of preterm birth, while active surveillance for grade 2 cervical intraepithelial neoplasia offers no active treatment. Topical therapy for human papillomavirus (HPV)-associated lower genital tract disease could address this gap, yet no agent is approved for intraepithelial neoplasia of the cervix, vagina, or vulva, and a 2026 systematic review left open whether cervical treatment reduces progression. Scarcity does not explain this: 52 randomized trials have evaluated adjuvant treatment after excision, but heterogeneity in phenotype, comparator, and endpoint, and incomplete access to primary reports limit their interpretability. Three problems recur. First, the target epithelial population differs by phenotype and mechanism, yet local exposure was seldom characterized, although measurement strategies are set out here. Second, some antiviral claims rely on systems that do not reproduce the differentiation-dependent HPV life cycle. Third, endpoints are read against spontaneous regression approaching the effect sought. Randomized evidence supports imiquimod as a non-surgical option for appropriately selected women with vulvar high-grade squamous intraepithelial lesions; cervical conclusions depend on comparator and endpoint. We propose a conceptual eight-element sequence from clinical intention to inference, an interpretive aid, and not a validated appraisal instrument. Future studies should prespecify these elements and characterize exposure where feasible.<\/jats:p>","DOI":"10.3390\/jcm15197631","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:10:48Z","timestamp":1790932248000},"page":"7631","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Active Compound to Target Epithelium: Local Delivery, Preclinical Model Validity, and Clinical Endpoint Interpretation in Topical Therapy for HPV-Associated Lower Genital Tract Disease\u2014A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"given":"Sandra Teodora","family":"Gavril","sequence":"first","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u0103zvan","family":"Popovici","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Cuza Voda Hospital, 700038 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iustina Petra","family":"Solomon Condriuc","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasile Adrian","family":"Sescu","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Cuza Voda Hospital, 700038 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1955-3521","authenticated-orcid":false,"given":"Raluca","family":"Haba","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Cuza Voda Hospital, 700038 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca Anamaria","family":"Mogo\u0219","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Cuza Voda Hospital, 700038 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2488-2154","authenticated-orcid":false,"given":"Claudia Florida","family":"Costea","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Department of Ophthalmology, Emergency Clinical Hospital \u201cProf. Dr. Nicolae Oblu\u201d, 700309 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9112-7039","authenticated-orcid":false,"given":"Alexandru","family":"C\u0103r\u0103uleanu","sequence":"additional","affiliation":[{"name":"\u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Iasi, Romania"},{"name":"Cuza Voda Hospital, 700038 Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"i3633","DOI":"10.1136\/bmj.i3633","article-title":"Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: Systematic review and meta-analysis","volume":"354","author":"Kyrgiou","year":"2016","journal-title":"BMJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S1470-2045(22)00334-5","article-title":"Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: A systematic review and network meta-analysis","volume":"23","author":"Athanasiou","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/S1470-2045(24)00524-2","article-title":"Active surveillance of cervical intraepithelial neoplasia grade 2: 2025 BSCCP and ESGO consensus statement","volume":"26","author":"Kyrgiou","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"k499","DOI":"10.1136\/bmj.k499","article-title":"Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: Systematic review and meta-analysis","volume":"360","author":"Tainio","year":"2018","journal-title":"BMJ"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"462.e1","DOI":"10.1016\/j.ajog.2025.05.039","article-title":"Active surveillance of cervical intraepithelial neoplasia grade 2 is not associated with an increased risk of noncervical anogenital human papillomavirus-related cancer and precancer: A population-based cohort study","volume":"233","author":"Eriksen","year":"2025","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_6","unstructured":"World Health Organization (2021). WHO Guideline for Screening and Treatment of Cervical Pre-Cancer Lesions for Cervical Cancer Prevention, World Health Organization. [2nd ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.2023.13174","article-title":"Cervical cancer screening: A review","volume":"330","author":"Perkins","year":"2023","journal-title":"JAMA"},{"key":"ref_8","unstructured":"(2026, August 23). Adjuvant Self-Administered Intravaginal 5-Fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-Positive Women in East Africa. ClinicalTrials.gov Identifier NCT05362955, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05362955."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Adewumi, K., Kachoria, A.G., Adoyo, E., Rop, M., Owaya, A., Tang, J.H., Rahangdale, L., and Mungo, C. (2025). Women\u2019s experiences and acceptability of self-administered, home delivered, intravaginal 5-fluorouracil cream for cervical precancer treatment in Kenya. Front. Reprod. Health, 7.","DOI":"10.3389\/frph.2025.1487264"},{"key":"ref_10","unstructured":"U.S. Food and Drug Administration (2026, August 23). Imiquimod Cream, 5%: Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (2006). Veregen (Sinecatechins) Ointment, 15%, Prescribing Information."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/S0140-6736(22)00469-X","article-title":"Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: A multicentre, randomised, phase 3, non-inferiority trial","volume":"399","author":"Trutnovsky","year":"2022","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S1470-2045(14)70456-5","article-title":"Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3VIN): A multicentre, open-label, randomised, phase 2 trial","volume":"15","author":"Tristram","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ijgo.14953","article-title":"The efficacy of topical imiquimod in high-grade cervical intraepithelial neoplasia: A systematic review and meta-analysis","volume":"164","author":"Kengsakul","year":"2024","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2022.01.033","article-title":"Topical imiquimod compared with conization to treat cervical high-grade squamous intraepithelial lesions: Multicenter, randomized controlled trial","volume":"165","author":"Polterauer","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"314.e1","DOI":"10.1016\/j.ajog.2013.12.042","article-title":"Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: A randomized controlled trial","volume":"210","author":"Rahangdale","year":"2014","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_17","first-page":"954","article-title":"Vaginal 5-fluorouracil for high-grade cervical dysplasia in human immunodeficiency virus infection: A randomized trial","volume":"94","author":"Maiman","year":"1999","journal-title":"Obstet. Gynecol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ygyno.2019.12.035","article-title":"A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2\/3 (CIN2\/3)","volume":"157","author":"Trimble","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_19","unstructured":"Takeda (2026, August 22). A Study of 851B Gel in Adult Females with Cervical Human Papillomavirus Infection. ClinicalTrials.gov Identifier NCT00312286, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00312286."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102729","DOI":"10.1016\/j.ijgc.2025.102729","article-title":"Efficacy of topical treatments for high-risk human papillomavirus in preventing CIN II+ lesions: A systematic review","volume":"36","author":"Pareja","year":"2026","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/AOG.0b013e31825bc6e8","article-title":"Treatment of cervical intraepithelial neoplasia with topical imiquimod: A randomized controlled trial","volume":"120","author":"Grimm","year":"2012","journal-title":"Obstet. Gynecol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"200268","DOI":"10.1016\/j.tvr.2023.200268","article-title":"The human papillomavirus twilight zone: Latency, immune control and subclinical infection","volume":"16","author":"Doorbar","year":"2023","journal-title":"Tumour Virus Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1323879","article-title":"Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation","volume":"257","author":"Meyers","year":"1992","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"10516","DOI":"10.1073\/pnas.1202684109","article-title":"A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer","volume":"109","author":"Herfs","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/PAS.0000000000001818","article-title":"Cervical precancers originate from infected proliferating reserve cells: A comparative histologic and genetic study of thin and thick high-grade squamous intraepithelial lesions","volume":"46","author":"Regauer","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"199068","DOI":"10.1016\/j.virusres.2023.199068","article-title":"Elimination of reserve cells for prevention of HPV-associated cervical cancer","volume":"329","author":"Reich","year":"2023","journal-title":"Virus Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1073\/pnas.0911748107","article-title":"Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses","volume":"107","author":"Lai","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100608","DOI":"10.1016\/j.gore.2020.100608","article-title":"Topical therapies for the treatment of cervical intraepithelial neoplasia (CIN) 2\u20133: A narrative review","volume":"33","author":"Desravines","year":"2020","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jiph.2023.06.016","article-title":"Natural and synthetic drugs and formulations for intravaginal HPV clearance","volume":"16","author":"Khamjan","year":"2023","journal-title":"J. Infect. Public Health"},{"key":"ref_30","first-page":"e357","article-title":"Sinecatechins ointment 10% (Veregen) for genital warts: Percutaneous penetration of epigallocatechin gallate concentrations in the stratum corneum collected by adhesive tape stripping method","volume":"32","author":"Soltanipoor","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_31","unstructured":"U.S. Food and Drug Administration (2026, September 14). PAPZIMEOS (Zopapogene Imadenovec-Drba), Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/papzimeos."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.antiviral.2009.10.019","article-title":"Epithelial raft cultures for investigations of virus growth, pathogenesis and efficacy of antiviral agents","volume":"85","author":"Andrei","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA: A scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1523-1747.2000.00833.x","article-title":"Imiquimod, a topical immune response modifier, induces migration of Langerhans cells","volume":"114","author":"Suzuki","year":"2000","journal-title":"J. Investig. Dermatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102038","DOI":"10.1016\/j.eclinm.2023.102038","article-title":"Efficacy and safety of a self-applied carrageenan-based gel to prevent human papillomavirus infection in sexually active young women (CATCH study): An exploratory phase IIB randomised, placebo-controlled trial","volume":"60","author":"Laurie","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/1471-0528.15124","article-title":"Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: Results from a multicentre, randomised, phase II trial (RT3VIN)","volume":"125","author":"Hurt","year":"2018","journal-title":"BJOG"},{"key":"ref_38","first-page":"CD007924","article-title":"Medical interventions for high-grade vulval intraepithelial neoplasia","volume":"2015","author":"Pepas","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cokan, A., Paki\u017e, M., Serdin\u0161ek, T., Dovnik, A., Kodri\u010d, T., Rep\u0161e Fokter, A., Kavalar, R., and But, I. (2021). Comparison of conservative treatment of cervical intraepithelial lesions with imiquimod with standard excisional technique using LLETZ: A randomized controlled trial. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245777"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.ygyno.2026.01.048","article-title":"Phase 1b\/2a randomized, double-blind study demonstrates potential of ABI-2280, a novel antiviral vaginal insert for the treatment of persistent high-risk\/oncogenic HPV infection","volume":"208","author":"Huh","year":"2026","journal-title":"Gynecol. Oncol."},{"key":"ref_41","unstructured":"(2026, September 14). A Study of ABI-2280 Vaginal Insert (Previously Referred to as ABI-2280 Vaginal Tablet) in Participants with Cervical Intraepithelial Neoplasia. ClinicalTrials.gov Identifier NCT05502367, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05502367."},{"key":"ref_42","unstructured":"(2026, September 14). A Randomized, Placebo-Controlled Study to Evaluate Clearance of High-Risk Human Papillomavirus and Safety After Administration of ABI-2280 Vaginal Inserts. ClinicalTrials.gov Identifier NCT06491446, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06491446."},{"key":"ref_43","unstructured":"Antiva Biosciences (2026, January 10\u201313). Data from the Phase 1b\/2 Study of ABI-2280 for Treatment of Cervical High-Risk HPV Infection. Proceedings of the Society of Gynecologic Oncology Annual Meeting on Women\u2019s Cancer, San Juan, PR, USA."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12985-023-02001-6","article-title":"Evaluation of the clinical efficacy of vaginal treatment options for persistent high-risk human papillomavirus infection after excisional treatment of cervical high-grade squamous intraepithelial lesions: A systematic review and Bayesian network meta-analysis","volume":"20","author":"Tang","year":"2023","journal-title":"Virol. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1097\/AOG.0b013e3181719b60","article-title":"Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: A randomized controlled trial","volume":"111","author":"Tatti","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/j.1468-3083.2007.02441.x","article-title":"A randomized, double-blind, four-arm parallel-group, placebo-controlled phase II\/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts","volume":"21","author":"Gross","year":"2007","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/1471-0528.16574","article-title":"Sinecatechins ointment as a potential novel treatment for usual type vulval intraepithelial neoplasia: A single-centre double-blind randomised control study","volume":"128","author":"Yap","year":"2021","journal-title":"BJOG"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pvr.2019.02.004","article-title":"Whole tissue cervical mapping of HPV infection: Molecular evidence for focal latent HPV infection in humans","volume":"7","author":"Hammer","year":"2019","journal-title":"Papillomavirus Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Xiao, J., Chen, Z., Xiao, Y., Sui, L., Wang, C., and Cong, Q. (2023). Vulvar squamous intraepithelial neoplasia epithelial thickness in hairy and non-hairy sites: A single center experience from China. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1254820"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jps.21132","article-title":"Dilution of microbicide gels with vaginal fluid and semen simulants: Effect on rheological properties and coating flow","volume":"97","author":"Lai","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1111\/j.1365-2133.2008.08520.x","article-title":"Topical Polyphenon E in the treatment of external genital and perianal warts: A randomized controlled trial","volume":"158","author":"Stockfleth","year":"2008","journal-title":"Br. J. Dermatol."},{"key":"ref_52","first-page":"104","article-title":"A case report and literature review of delayed telogen effluvium after topical imiquimod use in treating a cervical high-grade squamous intraepithelial lesion","volume":"43","author":"Cokan","year":"2022","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"O\u2019Hanlon, D.E., Come, R.A., and Moench, T.R. (2019). Vaginal pH measured in vivo: Lactobacilli determine pH and lactic acid concentration. BMC Microbiol., 19.","DOI":"10.1186\/s12866-019-1388-8"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0010-7824(99)00010-4","article-title":"A vaginal fluid simulant","volume":"59","author":"Owen","year":"1999","journal-title":"Contraception"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Falavigna, M., Pattacini, M., Wibel, R., Sonvico, F., \u0160kalko-Basnet, N., and Flaten, G.E. (2020). The Vaginal-PVPA: A vaginal mucosa-mimicking in vitro permeation tool for evaluation of mucoadhesive formulations. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060568"},{"key":"ref_56","first-page":"14B.3.1","article-title":"Using organotypic (raft) epithelial tissue cultures for the biosynthesis and isolation of infectious human papillomaviruses","volume":"34","author":"Ozbun","year":"2014","journal-title":"Curr. Protoc. Microbiol."},{"key":"ref_57","first-page":"171","article-title":"Propagation of infectious, high-risk HPV in organotypic raft culture","volume":"119","author":"Meyers","year":"2005","journal-title":"Methods Mol. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.virol.2004.02.011","article-title":"Propagation, infection, and neutralization of authentic HPV16 virus","volume":"322","author":"Christensen","year":"2004","journal-title":"Virology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1002\/cpmc.129","article-title":"3D oral and cervical tissue models for studying papillomavirus host-pathogen interactions","volume":"59","author":"Jackson","year":"2020","journal-title":"Curr. Protoc. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e00180-19","DOI":"10.1128\/mBio.00180-19","article-title":"A novel in vivo infection model to study papillomavirus-mediated disease of the female reproductive tract","volume":"10","author":"Spurgeon","year":"2019","journal-title":"mBio"},{"key":"ref_61","unstructured":"(2026, September 14). A Safety and Efficacy Study of Transcription Activator-like Effector Nucleases and Clustered Regularly Interspaced Short Palindromic Repeat\/Cas9 in the Treatment of HPV-Related Cervical Intraepithelial Neoplasia I. ClinicalTrials.gov Identifier NCT03057912, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03057912."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1073\/pnas.1002611107","article-title":"Vaginal microbiome of reproductive-age women","volume":"108","author":"Ravel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41564-022-01083-2","article-title":"Towards a deeper understanding of the vaginal microbiota","volume":"7","author":"France","year":"2022","journal-title":"Nat. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/mi.2016.129","article-title":"Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota","volume":"10","author":"Shannon","year":"2017","journal-title":"Mucosal Immunol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7631\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:20:51Z","timestamp":1790932851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":64,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197631"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197631","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]}}}